First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting

Diagnosis and treatment of tuberculosis infection (TBI) are the core elements of tuberculosis elimination. Interferon gamma release assays have advantages over the tuberculin skin test, although their implementation in low-resource settings is challenging. The performance of a novel digital lateral...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2023-02, Vol.18 (2), p.e0279882-e0279882
Main Authors: Aziz, Zirwatul Adilah, Noordin, Noorliza Mohamad, Wan Mohd, Wan Mazlina, Kasim, Mohd Amin
Format: Article
Language:English
Subjects:
Agreements
Analysis
Antigens
Assaying
Biological response modifiers
Biology and Life Sciences
Care and treatment
Computer and Information Sciences
Coronaviruses
COVID-19
Diagnosis
Engineering and Technology
FDA approval
Health aspects
Humans
Incidence
Infections
Informed consent
Interferon
Interferon-gamma Release Tests
Laboratories
Latent Tuberculosis - diagnosis
Medical diagnosis
Medical research
Medicine and Health Sciences
Nanoparticles
Patients
Performance evaluation
Prevention
Public health
Skin tests
Tuberculin
Tuberculin Test
Tuberculosis
Tuberculosis - diagnosis
Tuberculosis - epidemiology
γ-Interferon
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diagnosis and treatment of tuberculosis infection (TBI) are the core elements of tuberculosis elimination. Interferon gamma release assays have advantages over the tuberculin skin test, although their implementation in low-resource settings is challenging. The performance of a novel digital lateral flow assay QIAreach® QuantiFERON®-TB (QIAreach QFT) against the QuantiFERON®-TB Gold Plus (QFT-Plus) assay was evaluated in an intermediate incidence setting (Malaysia) according to the manufacturer's instructions. Individuals aged 4-82 years, who were candidates for TB infection screening for contact investigation were prospectively recruited. On 196 samples, the QIAreach-QFT showed a positive percent agreement (sensitivity) was 96.5% (CI 87.9-99.6%), a negative percent agreement (specificity) 94.2% (CI 88.4% to 97.6%) and an overall percentage of agreement was 94.9% (95% CI 90.6-97.6%) with a Cohen's κ of 0,88. Out of 196, 5.6% (11/196) samples gave an error result on QIAreach-QFT and 4.1% (8/196) samples gave indeterminate result on QFT-plus. The TTR for QIAreach QFT positive samples varied from 210-1200 seconds (20 min) and significantly correlated with IFN-γ level of QFT-Plus. QIAreach QFT could be considered an accurate and reliable point-of-need test to diagnose TB infection helping to achieve the WHO End TB programme goals even in decentralised settings where laboratory expertise and infrastructure may be limited.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0279882